BR112013004850B1 - uso de um antagonista do tgf-b na preparação de um medicamento para tratamento de infarto do miocárdio - Google Patents
uso de um antagonista do tgf-b na preparação de um medicamento para tratamento de infarto do miocárdio Download PDFInfo
- Publication number
- BR112013004850B1 BR112013004850B1 BR112013004850A BR112013004850A BR112013004850B1 BR 112013004850 B1 BR112013004850 B1 BR 112013004850B1 BR 112013004850 A BR112013004850 A BR 112013004850A BR 112013004850 A BR112013004850 A BR 112013004850A BR 112013004850 B1 BR112013004850 B1 BR 112013004850B1
- Authority
- BR
- Brazil
- Prior art keywords
- tgf
- antibody
- domain
- seq
- fact
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37931510P | 2010-09-01 | 2010-09-01 | |
| PCT/US2011/001536 WO2012030394A1 (en) | 2010-09-01 | 2011-09-01 | Treatment of myocardial infarction using tgf - beta antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013004850A2 BR112013004850A2 (pt) | 2016-05-31 |
| BR112013004850B1 true BR112013004850B1 (pt) | 2020-04-07 |
Family
ID=44654454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013004850A BR112013004850B1 (pt) | 2010-09-01 | 2011-09-01 | uso de um antagonista do tgf-b na preparação de um medicamento para tratamento de infarto do miocárdio |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20130330352A1 (https=) |
| EP (1) | EP2611831B1 (https=) |
| JP (2) | JP6377348B2 (https=) |
| KR (1) | KR101939965B1 (https=) |
| CN (1) | CN103201292B (https=) |
| BR (1) | BR112013004850B1 (https=) |
| CA (1) | CA2809568C (https=) |
| CL (1) | CL2013000586A1 (https=) |
| ES (1) | ES2715177T3 (https=) |
| IL (1) | IL225018A (https=) |
| MX (1) | MX354535B (https=) |
| MY (1) | MY165160A (https=) |
| NZ (2) | NZ608813A (https=) |
| PH (1) | PH12013500411A1 (https=) |
| PL (1) | PL2611831T3 (https=) |
| RU (1) | RU2637088C2 (https=) |
| SG (2) | SG187953A1 (https=) |
| TR (1) | TR201903101T4 (https=) |
| WO (1) | WO2012030394A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1008628A2 (pt) * | 2009-02-18 | 2016-03-01 | Cormatrix Cardiovascular Inc | método de tratamento ou prevenção de arritmia cardíaca em um indivíduo |
| PT2971048T (pt) * | 2013-03-11 | 2019-02-06 | Genzyme Corp | Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios |
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| HK1256638A1 (zh) | 2015-08-04 | 2019-09-27 | Acceleron Pharma Inc. | 用於治疗骨髓增生性病症的方法 |
| DK3368571T5 (da) | 2015-10-30 | 2024-09-30 | Univ California | Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf |
| TW201726744A (zh) | 2016-01-11 | 2017-08-01 | 奧托德里克有限公司 | 用於檢測奧美沙坦(olmesartan)及改善治療高血壓之遵從性的組成物、裝置及方法 |
| US20170218040A1 (en) * | 2016-02-02 | 2017-08-03 | Julio A. Camarero Palao | Proteolically resistant cyclotides with angiotensin 1-7 like activity |
| JP2019533003A (ja) * | 2016-08-11 | 2019-11-14 | プレシセラ，インコーポレイテッド | ＴＧＦ−βアンタゴニストコンジュゲート |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| AU2021339468A1 (en) * | 2020-09-10 | 2023-03-30 | Implicit Bioscience Limited | Therapeutic methods and agents for the treatment of myocardial infarction |
| US20250034212A1 (en) | 2021-09-30 | 2025-01-30 | Peptidream Inc. | Peptide |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| US7763580B2 (en) * | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| CN1961003B (zh) * | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| WO2006083779A2 (en) | 2005-01-31 | 2006-08-10 | Mylan Laboratories, Inc. | Pharmaceutical composition comprising hydroxylated nebivolol |
| WO2006086469A2 (en) * | 2005-02-08 | 2006-08-17 | Genzyme Corporation | Antibodies to tgfbeta |
| AU2010206543A1 (en) * | 2009-01-26 | 2011-07-07 | Intermune, Inc. | Methods for treating acute myocardial infarctions and associated disorders |
| ITMI20110376A1 (it) | 2011-03-10 | 2012-09-11 | Wilic Sarl | Aerogeneratore raffreddato a fluido |
-
2011
- 2011-09-01 MY MYPI2013000675A patent/MY165160A/en unknown
- 2011-09-01 NZ NZ608813A patent/NZ608813A/en not_active IP Right Cessation
- 2011-09-01 CN CN201180052346.0A patent/CN103201292B/zh not_active Expired - Fee Related
- 2011-09-01 WO PCT/US2011/001536 patent/WO2012030394A1/en not_active Ceased
- 2011-09-01 EP EP11758276.7A patent/EP2611831B1/en active Active
- 2011-09-01 PH PH1/2013/500411A patent/PH12013500411A1/en unknown
- 2011-09-01 MX MX2013002390A patent/MX354535B/es active IP Right Grant
- 2011-09-01 CA CA2809568A patent/CA2809568C/en not_active Expired - Fee Related
- 2011-09-01 TR TR2019/03101T patent/TR201903101T4/tr unknown
- 2011-09-01 US US13/819,393 patent/US20130330352A1/en not_active Abandoned
- 2011-09-01 RU RU2013114365A patent/RU2637088C2/ru active
- 2011-09-01 SG SG2013013875A patent/SG187953A1/en unknown
- 2011-09-01 NZ NZ624382A patent/NZ624382A/en not_active IP Right Cessation
- 2011-09-01 KR KR1020137008326A patent/KR101939965B1/ko not_active Expired - Fee Related
- 2011-09-01 ES ES11758276T patent/ES2715177T3/es active Active
- 2011-09-01 BR BR112013004850A patent/BR112013004850B1/pt not_active IP Right Cessation
- 2011-09-01 PL PL11758276T patent/PL2611831T3/pl unknown
- 2011-09-01 JP JP2013527063A patent/JP6377348B2/ja not_active Expired - Fee Related
- 2011-09-01 SG SG10201506909PA patent/SG10201506909PA/en unknown
-
2013
- 2013-02-28 CL CL2013000586A patent/CL2013000586A1/es unknown
- 2013-02-28 IL IL225018A patent/IL225018A/en active IP Right Grant
-
2016
- 2016-12-12 US US15/376,358 patent/US10633437B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 JP JP2017083499A patent/JP2017193543A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TR201903101T4 (tr) | 2019-03-21 |
| PL2611831T3 (pl) | 2019-05-31 |
| US20130330352A1 (en) | 2013-12-12 |
| JP6377348B2 (ja) | 2018-08-22 |
| CA2809568C (en) | 2019-06-11 |
| CN103201292A (zh) | 2013-07-10 |
| CL2013000586A1 (es) | 2013-08-30 |
| KR101939965B1 (ko) | 2019-01-18 |
| NZ608813A (en) | 2014-11-28 |
| MX2013002390A (es) | 2013-08-27 |
| WO2012030394A1 (en) | 2012-03-08 |
| CA2809568A1 (en) | 2012-03-08 |
| CN103201292B (zh) | 2016-09-14 |
| EP2611831A1 (en) | 2013-07-10 |
| ES2715177T3 (es) | 2019-06-03 |
| KR20130111550A (ko) | 2013-10-10 |
| SG10201506909PA (en) | 2015-10-29 |
| PH12013500411A1 (en) | 2022-03-30 |
| IL225018A (en) | 2017-11-30 |
| US20170233465A1 (en) | 2017-08-17 |
| SG187953A1 (en) | 2013-03-28 |
| EP2611831B1 (en) | 2018-12-12 |
| MY165160A (en) | 2018-02-28 |
| JP2017193543A (ja) | 2017-10-26 |
| JP2013542179A (ja) | 2013-11-21 |
| RU2013114365A (ru) | 2014-10-10 |
| BR112013004850A2 (pt) | 2016-05-31 |
| US10633437B2 (en) | 2020-04-28 |
| NZ624382A (en) | 2015-05-29 |
| AU2011296574B2 (en) | 2015-12-03 |
| MX354535B (es) | 2018-03-09 |
| AU2011296574A1 (en) | 2013-03-21 |
| RU2637088C2 (ru) | 2017-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013004850B1 (pt) | uso de um antagonista do tgf-b na preparação de um medicamento para tratamento de infarto do miocárdio | |
| JP6259503B2 (ja) | 眼疾患の治療 | |
| ES2400458T3 (es) | Métodos de administración de anticuerpos anti-TNF-alfa | |
| KR101414847B1 (ko) | 페길화된 Ａβ ＦＡＢ | |
| JP2019069973A (ja) | ｐＨ範囲で結合性が異なる薬物動態改善のための抗ＴＦＰＩ抗体変異体 | |
| TW201002344A (en) | Monoclonal antibodies against the RGM a protein and uses thereof | |
| JP2010509369A (ja) | 加齢黄斑変性症を処置するための方法 | |
| CN104151427A (zh) | 针对TGFβ的抗体 | |
| EA031436B1 (ru) | Водная фармацевтическая композиция, содержащий ее предварительно заполненный шприц и применение композиции в лечении аутоиммунных заболеваний | |
| HK1245111A1 (zh) | IL-1β抗体及其结合片段的心血管相关用途 | |
| US20230116380A1 (en) | Long-acting gm-csf and methods of use | |
| KR20200044023A (ko) | 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물 | |
| AU2011296574B9 (en) | Treatment of myocardial infarction using TGF - beta antagonists | |
| HK1187356A (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| HK1187356B (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| HK1181788B (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| HK1181788A (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| HK40075201B (zh) | 稳定的水性抗-tfpi抗体制剂 | |
| HK1201859B (zh) | 针对TGFβ的抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/09/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2686 DE 28-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |